Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NT-112 by Neogene Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
NT-112 is under clinical development by Neogene Therapeutics and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
NT-112 by Neogene Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
NT-112 is under clinical development by Neogene Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
NT-112 by Neogene Therapeutics for Endometrial Cancer: Likelihood of Approval
NT-112 is under clinical development by Neogene Therapeutics and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
NT-112 by Neogene Therapeutics for Solid Tumor: Likelihood of Approval
NT-112 is under clinical development by Neogene Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
NT-112 by Neogene Therapeutics for Colorectal Cancer: Likelihood of Approval
NT-112 is under clinical development by Neogene Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...